English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/111153
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10

AutorGallego, Oriol ; Ruiz, Francesc Xavier; Ardèvol, Albert; Domínguez, Marta ; Álvarez, Rosana; Lera, Ángel R. de; Rovira, Carme; Farrés, Jaume; Fita, Ignacio ; Parés, Xavier
Palabras claveProtein structure
Retinoic acid
Tolrestat
Aldo-keto reductases
Aldose reductase
Fecha de publicación26-dic-2007
EditorNational Academy of Sciences (U.S.)
CitaciónProceedings of the National Academy of Sciences of the United States of America 104(52): 20764-20769 (2007)
ResumenAKR1B10 is a human aldo-keto reductase (AKR) found to be elevated in several cancer types and in precancerous lesions. In vitro, AKR1B10 exhibits a much higher retinaldehyde reductase activity than any other human AKR, including AKR1B1 (aldose reductase). We here demonstrate that AKR1B10 also acts as a retinaldehyde reductase in vivo. This activity may be relevant in controlling the first step of retinoic acid synthesis. Up-regulation of AKR1B10, resulting in retinoic acid depletion, may lead to cellular proliferation. Both in vitro and in vivo activities of AKR1B10 were inhibited by tolrestat, an AKR1B1 inhibitor developed for diabetes treatment. The crystal structure of the ternary complex AKR1B10-NADP+-tolrestat was determined at 1.25-Å resolution. Molecular dynamics models of AKR1B10 and AKR1B1 with retinaldehyde isomers and site-directed mutagenesis show that subtle differences at the entrance of the retinoid-binding site, especially at position 125, are determinant for the all-trans-retinaldehyde specificity of AKR1B10. Substitutions in the retinaldehyde cyclohexene ring also influence the specificity. These structural features should facilitate the design of specific inhibitors, with potential use in cancer and diabetes treatments. © 2007 by The National Academy of Sciences of the USA.
Versión del editorhttp://dx.doi.org/10.1073/pnas.0705659105
URIhttp://hdl.handle.net/10261/111153
DOI10.1073/pnas.0705659105
Identificadoresdoi: 10.1073/pnas.0705659105
issn: 0027-8424
Aparece en las colecciones: (IBMB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.